A recent rat study implicated FGF2 signaling in the antidepressant effects of high-frequency repetitive transcranial magnetic stimulation, attaching additional significance to this pathway in the treatment of depression (Yan et al., 2022). The gene discussed is FGF2; the disease is depressive symptom measurement.